Zobrazeno 1 - 10
of 1 233
pro vyhledávání: '"Programmed Death Ligand-1"'
Publikováno v:
Journal of Nanobiotechnology, Vol 22, Iss 1, Pp 1-29 (2024)
Abstract Recombinant oncolytic adenovirus offers a novel and promising cancer treatment approach, but its standalone efficacy remains limited. This study investigates a combination treatment strategy by co-administering recombinant oncolytic Adv-load
Externí odkaz:
https://doaj.org/article/decc8693b1134e14b11ad1e8a7251da0
Autor:
Le An, Rui Shao, Chenchen Hang, Xingsheng Wang, Luying Zhang, Hao Cui, Jingfei Yu, Zhenyu Shan, Ziren Tang
Publikováno v:
Resuscitation Plus, Vol 20, Iss , Pp 100822- (2024)
Background: Out-of-hospital cardiac arrest (OHCA) is a major public health problem. Acute respiratory distress syndrome (ARDS) is a common condition in OHCA patients. We investigated the relationship between the expression of programmed death-1 (PD-1
Externí odkaz:
https://doaj.org/article/e90254b97c3f4aa09d914c3652ab5e4e
Autor:
Sean T Evans, Yash Jani, Caroline S Jansen, Ahmet Yildirim, Ecem Kalemoglu, Mehmet Asim Bilen
Publikováno v:
Cancer Biology & Therapy, Vol 25, Iss 1 (2024)
The introduction of novel immunotherapies has significantly transformed the treatment landscape of genitourinary (GU) cancers, even becoming the standard of care in some settings. One such type of immunotherapy, immune checkpoint inhibitors (ICIs) li
Externí odkaz:
https://doaj.org/article/082b3f99543f4a1ea7b9fa6358747071
Autor:
Naoko Shigeta, Shuji Murakami, Tomoyuki Yokose, Tetsuya Isaka, Kanako Shinada, Takuya Nagashima, Hiroyuki Adachi, Shunsuke Shigefuku, Kotaro Murakami, Jun Miura, Noritake Kikunishi, Kozue Watabe, Haruhiro Saito, Hiroyuki Ito
Publikováno v:
Thoracic Cancer, Vol 15, Iss 17, Pp 1343-1349 (2024)
Abstract Background Atezolizumab, one of the immune checkpoint inhibitors, has been approved as an adjuvant treatment following resection and platinum‐based chemotherapy in patients with stage II–IIIA non‐small cell lung cancer with 1% or more
Externí odkaz:
https://doaj.org/article/71efbf3a4aae40ef8a8cbd9e59852ae7
Publikováno v:
Translational Oncology, Vol 46, Iss , Pp 102024- (2024)
Background: Studies have highlighted the important role of cell division cycle associated 5 (CDCA5) in tumor-associated immune dysfunction. We studied immune dysfunction based on CDCA5 expression in lung adenocarcinoma and investigated its potential
Externí odkaz:
https://doaj.org/article/322d3526252a48038c36aa251bb311ad
Autor:
An, Le a, 1, Shao, Rui a, 1, Hang, Chenchen a, Wang, Xingsheng a, Zhang, Luying a, Cui, Hao a, Yu, Jingfei a, Shan, Zhenyu a, Tang, Ziren a, b, ⁎
Publikováno v:
In Resuscitation Plus December 2024 20
Autor:
Meiyan Zhu, Meng Jin, Xiao Zhao, Shunli Shen, Yihan Chen, Han Xiao, Guangyan Wei, Qiang He, Bin Li, Zhenwei Peng
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-11 (2024)
Abstract Background Unresectable intrahepatic cholangiocarcinoma (iCCA) has a poor prognosis despite treatment with standard combination chemotherapy. We aimed to evaluate the efficacy and safety of radiotherapy in combination with an anti-PD-1 antib
Externí odkaz:
https://doaj.org/article/58964a77ef0246d8a2d230110d1e01b7
Publikováno v:
Polish Journal of Pathology, Vol 75, Iss 1, Pp 25-35 (2024)
Small cell lung carcinoma (SCLC) is characterized by rapid growth and an aggressive clinical course. Standard therapy regimes have limited effects on disease course; therefore the prognosis of SCLC is poor. In the current study, the frequency of prog
Externí odkaz:
https://doaj.org/article/048a0e5b8c244690820728c4c96e02c7
Autor:
Zaigang Zhou, Xin Jiang, Lei Yi, Cheng Li, Haoxiang Wang, Wei Xiong, Zhipeng Li, Jianliang Shen
Publikováno v:
Advanced Science, Vol 11, Iss 26, Pp n/a-n/a (2024)
Abstract Currently, the typical combination therapy of programmed death ligand‐1 (PD‐L1) antibodies with radiotherapy (RT) still exhibits impaired immunogenic antitumor response in clinical due to lessened DNA damage and acquired immune tolerance
Externí odkaz:
https://doaj.org/article/89fdf6b883c046a6ab4d00aa0c36e3f9
Autor:
Stella Meireles Siqueira, Gabriella Campos-do-Carmo, Paulo Ricardo Garcia da Silva, Isabele Ávila Small, Andreia Cristina De Melo
Publikováno v:
Infectious Agents and Cancer, Vol 19, Iss 1, Pp 1-10 (2024)
Abstract Background Merkel cell carcinoma (MCC) comprises a rare malignant primary skin tumor presenting neuroendocrine differentiation. Recently, agents blocking the programmed cell death protein 1 and programmed cell death protein ligand 1 pathway
Externí odkaz:
https://doaj.org/article/63bd7945162d438e85b4afcc8d2e289f